Caris Downgrades Par Pharma (PRX) to Above Average
More News related to PRX
- Par Pharmaceutical to Host Analyst Day on December 3rd
- Par Pharma (PRX) Receives Final U.S. FDA Approval for Tramadol ER Doses
- Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
- Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Curren
- Par Pharma (PRX) Posts Q3 EPS of $0.76, Tops Views
More News related to Downgrades
- Moody's Downgrades Sprint Nextel's (S) Corporate Family Rating; Outlook Negative
- Comverge (COMV) Continuing Lower as Ardour Analyst Cuts to Hold
- Scotia Capital Downgrades New Gold Inc. (NGD) to Sector Underperform
- Craig-Hallum Downgrades ADC Telecom (ADCT) to Accumulate
- Wedbush Downgrades VeriSign (VRSN) to Neutral; Growth Catalysts Not Expected Until 2011
Caris & Co. downgrades Par Pharmaceutical Companies (NYSE: PRX) from Buy to Above Average.
This morning's downgrade follows Par's Q2 results reported yesterday morning. Despite beating the Street's quarterly estimates, shares of Par fell 8% yesterday, also gapping lower earlier today, but now trading in positive territory.
To see all the analyst action on shares of Par, visit our Analyst Ratings page.
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
